Halozyme Therapeutics, Inc. (HALO)
USD 57.78
(-3.33%)
USD 57.78
(-3.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 299.31 Million USD | 18.18% |
| 2022 | 253.28 Million USD | 194.53% |
| 2021 | 85.99 Million USD | 7.53% |
| 2020 | 79.97 Million USD | -63.33% |
| 2019 | 218.05 Million USD | 3.32% |
| 2018 | 211.05 Million USD | 3.23% |
| 2017 | 204.45 Million USD | 3.95% |
| 2016 | 196.69 Million USD | 47.6% |
| 2015 | 133.26 Million USD | 15.24% |
| 2014 | 115.63 Million USD | -10.35% |
| 2013 | 128.98 Million USD | 35.98% |
| 2012 | 94.85 Million USD | 25.36% |
| 2011 | 75.66 Million USD | 13.11% |
| 2010 | 66.89 Million USD | -6.85% |
| 2009 | 71.81 Million USD | 22.0% |
| 2008 | 58.86 Million USD | 85.64% |
| 2007 | 31.7 Million USD | 96.61% |
| 2006 | 16.12 Million USD | 18.27% |
| 2005 | 13.63 Million USD | 50.05% |
| 2004 | 9.08 Million USD | 11582.09% |
| 2003 | 77.79 Thousand USD | 0.4% |
| 2002 | 77.48 Thousand USD | 59.64% |
| 2001 | 48.53 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 56.74 Million USD | 4.62% |
| 2024 Q1 | 54.24 Million USD | -29.28% |
| 2024 Q3 | 77.46 Million USD | 36.5% |
| 2023 Q2 | 76.51 Million USD | 4.56% |
| 2023 Q3 | 72.93 Million USD | -4.68% |
| 2023 Q4 | 76.7 Million USD | 5.18% |
| 2023 FY | 299.31 Million USD | 18.18% |
| 2023 Q1 | 73.17 Million USD | 12.8% |
| 2022 Q3 | 78.36 Million USD | -7.11% |
| 2022 Q1 | 25.68 Million USD | 7.56% |
| 2022 Q2 | 84.36 Million USD | 228.42% |
| 2022 FY | 253.28 Million USD | 194.53% |
| 2022 Q4 | 64.86 Million USD | -17.22% |
| 2021 FY | 85.99 Million USD | 7.53% |
| 2021 Q4 | 23.88 Million USD | 10.28% |
| 2021 Q3 | 21.65 Million USD | 6.2% |
| 2021 Q2 | 20.39 Million USD | 1.6% |
| 2021 Q1 | 20.06 Million USD | 12.7% |
| 2020 Q2 | 19.92 Million USD | -12.57% |
| 2020 Q1 | 22.79 Million USD | -66.99% |
| 2020 Q3 | 19.44 Million USD | -2.39% |
| 2020 FY | 79.97 Million USD | -63.33% |
| 2020 Q4 | 17.8 Million USD | -8.44% |
| 2019 Q2 | 51.24 Million USD | 3.88% |
| 2019 Q3 | 48.43 Million USD | -5.49% |
| 2019 Q4 | 69.04 Million USD | 42.54% |
| 2019 FY | 218.05 Million USD | 3.32% |
| 2019 Q1 | 49.33 Million USD | -9.78% |
| 2018 Q1 | 51.53 Million USD | -8.22% |
| 2018 FY | 211.05 Million USD | 3.23% |
| 2018 Q4 | 54.68 Million USD | 8.49% |
| 2018 Q3 | 50.4 Million USD | -7.41% |
| 2018 Q2 | 54.43 Million USD | 5.64% |
| 2017 Q4 | 56.14 Million USD | 18.65% |
| 2017 Q3 | 47.32 Million USD | -8.01% |
| 2017 Q2 | 51.44 Million USD | 3.81% |
| 2017 Q1 | 49.55 Million USD | -7.51% |
| 2017 FY | 204.45 Million USD | 3.95% |
| 2016 Q3 | 45.46 Million USD | -2.76% |
| 2016 Q4 | 53.57 Million USD | 17.85% |
| 2016 FY | 196.69 Million USD | 47.6% |
| 2016 Q2 | 46.75 Million USD | -8.16% |
| 2016 Q1 | 50.9 Million USD | 32.79% |
| 2015 Q4 | 38.33 Million USD | 1.32% |
| 2015 Q3 | 37.83 Million USD | 22.02% |
| 2015 Q2 | 31 Million USD | 18.89% |
| 2015 Q1 | 26.08 Million USD | -7.12% |
| 2015 FY | 133.26 Million USD | 15.24% |
| 2014 Q2 | 27.4 Million USD | -13.47% |
| 2014 FY | 115.63 Million USD | -10.35% |
| 2014 Q1 | 31.66 Million USD | 4.57% |
| 2014 Q4 | 28.08 Million USD | -1.44% |
| 2014 Q3 | 28.49 Million USD | 3.98% |
| 2013 Q3 | 33.82 Million USD | -4.15% |
| 2013 FY | 128.98 Million USD | 35.98% |
| 2013 Q1 | 29.59 Million USD | 15.83% |
| 2013 Q4 | 30.28 Million USD | -10.47% |
| 2013 Q2 | 35.29 Million USD | 19.26% |
| 2012 Q4 | 25.54 Million USD | 1.63% |
| 2012 Q1 | 22.5 Million USD | 8.31% |
| 2012 Q3 | 25.13 Million USD | 16.04% |
| 2012 Q2 | 21.66 Million USD | -3.77% |
| 2012 FY | 94.85 Million USD | 25.36% |
| 2011 FY | 75.66 Million USD | 13.11% |
| 2011 Q1 | 17.19 Million USD | -16.41% |
| 2011 Q2 | 19.91 Million USD | 15.84% |
| 2011 Q3 | 17.77 Million USD | -10.73% |
| 2011 Q4 | 20.78 Million USD | 16.9% |
| 2010 Q4 | 20.56 Million USD | 29.98% |
| 2010 FY | 66.89 Million USD | -6.85% |
| 2010 Q3 | 15.82 Million USD | 3.54% |
| 2010 Q2 | 15.28 Million USD | 0.38% |
| 2010 Q1 | 15.22 Million USD | -19.7% |
| 2009 Q1 | 17.52 Million USD | -12.2% |
| 2009 FY | 71.81 Million USD | 22.0% |
| 2009 Q2 | 18.46 Million USD | 5.35% |
| 2009 Q4 | 18.96 Million USD | 12.42% |
| 2009 Q3 | 16.86 Million USD | -8.66% |
| 2008 Q3 | 13.53 Million USD | 5.95% |
| 2008 FY | 58.86 Million USD | 85.64% |
| 2008 Q4 | 19.96 Million USD | 47.52% |
| 2008 Q2 | 12.77 Million USD | 1.35% |
| 2008 Q1 | 12.6 Million USD | 12.15% |
| 2007 Q3 | 9.19 Million USD | 42.18% |
| 2007 Q4 | 11.23 Million USD | 22.22% |
| 2007 Q1 | 4.81 Million USD | -4.74% |
| 2007 FY | 31.7 Million USD | 96.61% |
| 2007 Q2 | 6.46 Million USD | 34.3% |
| 2006 Q1 | 3.72 Million USD | 3.02% |
| 2006 FY | 16.12 Million USD | 18.27% |
| 2006 Q3 | 3.83 Million USD | 8.93% |
| 2006 Q4 | 5.05 Million USD | 31.87% |
| 2006 Q2 | 3.51 Million USD | -5.51% |
| 2005 Q2 | 2.97 Million USD | -9.19% |
| 2005 Q4 | 3.61 Million USD | -4.42% |
| 2005 FY | 13.63 Million USD | 50.05% |
| 2005 Q3 | 3.78 Million USD | 27.3% |
| 2005 Q1 | 3.27 Million USD | 29.39% |
| 2004 Q4 | 2.52 Million USD | -22.53% |
| 2004 Q1 | 1.2 Million USD | 2705.06% |
| 2004 Q2 | 2.08 Million USD | 73.01% |
| 2004 FY | 9.08 Million USD | 11582.09% |
| 2004 Q3 | 3.26 Million USD | 56.2% |
| 2003 FY | 77.79 Thousand USD | 0.4% |
| 2003 Q1 | 11.07 Thousand USD | -42.93% |
| 2003 Q2 | 12.13 Thousand USD | 9.53% |
| 2003 Q4 | 43.04 Thousand USD | 229.98% |
| 2003 Q3 | 13.04 Thousand USD | 7.52% |
| 2002 Q3 | 25.72 Thousand USD | 38.11% |
| 2002 Q1 | 13.71 Thousand USD | 0.0% |
| 2002 Q4 | 19.41 Thousand USD | -24.56% |
| 2002 FY | 77.48 Thousand USD | 59.64% |
| 2002 Q2 | 18.62 Thousand USD | 35.83% |
| 2001 FY | 48.53 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -8.751% |
| Alkermes plc | 996.24 Million USD | 69.955% |
| Agenus Inc. | 78.18 Million USD | -282.843% |
| Aptorum Group Limited | 10.56 Thousand USD | -2832741.189% |
| Ardelyx, Inc. | 169.93 Million USD | -76.135% |
| Dyadic International, Inc. | 9.15 Million USD | -3170.271% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1245.068% |
| Lantern Pharma Inc. | 17.87 Million USD | -1574.266% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -4346.234% |
| Novavax, Inc. | 779.12 Million USD | 61.583% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -269.246% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -264.152% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1441.405% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -911.005% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -463.407% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 21.335% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1131.426% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -690.404% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -872.728% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -253.319% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1614.602% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -77.704% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -814.926% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -87.323% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 83.372% |
| AlloVir, Inc. | 180.93 Million USD | -65.43% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 32.849% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -908.416% |
| Bicycle Therapeutics plc | 216.92 Million USD | -37.984% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -74.121% |
| ChromaDex Corporation | 56.37 Million USD | -430.903% |
| Chimerix, Inc. | 93.38 Million USD | -220.507% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -2051.874% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -98.835% |
| CRISPR Therapeutics AG | 463.49 Million USD | 35.421% |
| Precision BioSciences, Inc. | 92.46 Million USD | -223.717% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -17.821% |
| Fortress Biotech, Inc. | 200.19 Million USD | -49.513% |
| Fortress Biotech, Inc. | 200.19 Million USD | -49.513% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -814.06% |
| ImmuCell Corporation | 9.61 Million USD | -3012.267% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -89.665% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1754.383% |
| Incyte Corporation | 1.19 Billion USD | 74.858% |
| Innoviva, Inc. | 132.15 Million USD | -126.492% |
| IO Biotech, Inc. | 91.44 Million USD | -227.327% |
| Jaguar Health, Inc. | 42.01 Million USD | -612.407% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -76.821% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -254.966% |
| ContextLogic Inc. | 387 Million USD | 22.657% |
| MiMedx Group, Inc. | 229.72 Million USD | -30.293% |
| MEI Pharma, Inc. | 34.78 Million USD | -760.48% |
| NextCure, Inc. | 67.63 Million USD | -342.536% |
| Onconetix, Inc. | 34.9 Million USD | -757.462% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -2248.329% |
| Opthea Limited | 191.96 Million USD | -55.921% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -10778.021% |
| Vaxcyte, Inc. | 468.04 Million USD | 36.049% |
| PDS Biotechnology Corporation | 43.04 Million USD | -595.357% |
| Precigen, Inc. | 84.18 Million USD | -255.565% |
| Pharming Group N.V. | 225.49 Million USD | -32.741% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -78.349% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -312.477% |
| PureTech Health plc | 144.59 Million USD | -107.002% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -129.78% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -22.092% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1131.426% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -30.889% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -869.954% |
| Acelyrin, Inc. | 422.06 Million USD | 29.082% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -2321274.283% |
| Summit Therapeutics Inc. | 87.68 Million USD | -241.352% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -707.571% |
| Senti Biosciences, Inc. | 94.7 Million USD | -216.053% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -142.259% |
| Elevation Oncology, Inc. | 45.44 Million USD | -558.638% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -915.705% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -7492.957% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -126.456% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -778.152% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -3441.806% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -65.095% |
| Seer, Inc. | 110.49 Million USD | -170.901% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -323.999% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -220.202% |
| ESSA Pharma Inc. | 32.13 Million USD | -831.465% |
| GlycoMimetics, Inc. | 39.28 Million USD | -661.909% |
| GT Biopharma, Inc. | 13.57 Million USD | -2104.758% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -36.159% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -48.829% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -15.377% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -427.349% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -453.473% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2911.961% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 25.831% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -1481.267% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -490.452% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -15.273% |
| Aptose Biosciences Inc. | 52.35 Million USD | -471.698% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1977.101% |
| Soligenix, Inc. | 7.79 Million USD | -3739.748% |
| Century Therapeutics, Inc. | 56.07 Million USD | -433.82% |
| Kura Oncology, Inc. | 165.8 Million USD | -80.525% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -161.397% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -3498.005% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -11961.303% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -177.923% |
| Autolus Therapeutics plc | 196.72 Million USD | -52.15% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -253.566% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -157.029% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1444.229% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 6.974% |
| GRI Bio, Inc. | 11.33 Million USD | -2541.818% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -4142.215% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -128.151% |
| IGM Biosciences, Inc. | 265.59 Million USD | -12.699% |
| INmune Bio, Inc. | 29.89 Million USD | -901.197% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -73.463% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -642.461% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1773.154% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1801.452% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -382.009% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -178.378% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -8.569% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 0.708% |
| Verastem, Inc. | 92.08 Million USD | -225.049% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1568.532% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -61.162% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -146.541% |
| Histogen Inc. | 14.27 Million USD | -1997.239% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1765.126% |
| Surrozen, Inc. | 18.55 Million USD | -1513.574% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1906.825% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -5780.238% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -401.596% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1067.068% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -536.766% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -3821.448% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -68.028% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -517.813% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -22.169% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1847.851% |
| Apollomics, Inc. | 54.14 Million USD | -452.859% |
| Amarin Corporation plc | 272.35 Million USD | -9.899% |
| Mesoblast Limited | 5.9 Million USD | -4971.467% |
| Turnstone Biologics Corp. | 78.33 Million USD | -282.085% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -22.61% |
| Synaptogenix, Inc. | 8.31 Million USD | -3500.232% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1952.091% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -18.281% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -798.042% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -3289.311% |
| Exelixis, Inc. | 1.58 Billion USD | 81.137% |
| Better Therapeutics, Inc. | 38.26 Million USD | -682.285% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -28.989% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 65.0% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2435.076% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -3621.978% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -897.96% |
| Gritstone bio, Inc. | 148.37 Million USD | -101.732% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -334.67% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1729.548% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1051.4% |
| Insmed Incorporated | 949.26 Million USD | 68.468% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1807.725% |
| MediWound Ltd. | 18.86 Million USD | -1486.379% |
| OmniAb, Inc. | 83.89 Million USD | -256.777% |
| Alector, Inc. | 248.8 Million USD | -20.304% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -27.746% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -472.846% |
| Zai Lab Limited | 547.47 Million USD | 45.328% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 24.918% |
| Aura Biosciences, Inc. | 84.99 Million USD | -252.176% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -21.114% |
| Immunic, Inc. | 99.22 Million USD | -201.662% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -88.236% |
| Veracyte, Inc. | 357.93 Million USD | 16.376% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 96.68% |
| FibroGen, Inc. | 398.11 Million USD | 24.816% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2006.39% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -4245.533% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -4100.523% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 90.806% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1056.874% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 5.442% |
| TG Therapeutics, Inc. | 198.47 Million USD | -50.809% |
| Galecto, Inc. | 35.62 Million USD | -740.144% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -635.624% |
| Fortrea Holdings Inc. | 457.3 Million USD | 34.547% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -451.454% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -936.491% |
| XBiotech Inc. | 37.51 Million USD | -697.969% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -334.67% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1349.552% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -110.697% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -202.113% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -170.348% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 68.764% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -937.677% |
| Vaxxinity, Inc. | 56.05 Million USD | -434.01% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 30.495% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1241.733% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -169.979% |
| NexImmune, Inc. | 28.16 Million USD | -962.636% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -5311.694% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1572.867% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 89.368% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1075.686% |
| Scopus BioPharma Inc. | 11.71 Million USD | -2455.025% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -135.568% |
| Ainos, Inc. | 12.95 Million USD | -2210.861% |
| Pluri Inc. | 22.48 Million USD | -1231.486% |
| Prothena Corporation plc | 282.4 Million USD | -5.989% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -49.643% |
| Celularity Inc. | 215.05 Million USD | -39.18% |
| Rallybio Corporation | 78.93 Million USD | -279.21% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1431.665% |
| MeiraGTx Holdings plc | 151.07 Million USD | -98.122% |
| Omeros Corporation | 94.75 Million USD | -215.9% |
| Humacyte, Inc. | 23.49 Million USD | -1173.856% |
| Immunocore Holdings plc | 308.04 Million USD | 2.831% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -8729.44% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -244.578% |
| Blueprint Medicines Corporation | 722.86 Million USD | 58.593% |
| CalciMedica, Inc. | 21.81 Million USD | -1271.948% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -300.908% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -86.444% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -74.738% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -1.484% |
| Pulmatrix, Inc. | 22.03 Million USD | -1258.19% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -765.706% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -236.819% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 45.733% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -312.562% |
| Cytokinetics, Incorporated | 173.61 Million USD | -72.406% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -769.63% |
| Nutriband Inc. | 5.73 Million USD | -5120.028% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -586.305% |
| Vor Biopharma Inc. | 126.03 Million USD | -137.486% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 74.83% |
| Evogene Ltd. | 27.79 Million USD | -977.071% |
| ProKidney Corp. | 151.52 Million USD | -97.541% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -303.529% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -3791.167% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 51.269% |
| CorMedix Inc. | 48.95 Million USD | -511.38% |
| BioLineRx Ltd. | 50.8 Million USD | -489.185% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -98.618% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -686.189% |
| Atai Life Sciences N.V. | 125.78 Million USD | -137.96% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -266.635% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -267.672% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -18.517% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -814.227% |
| MediciNova, Inc. | 10.9 Million USD | -2645.97% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -132.354% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -4023.108% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4870.266% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 37.166% |
| Biomea Fusion, Inc. | 126.13 Million USD | -137.3% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 77.183% |
| Mereo BioPharma Group plc | 35.84 Million USD | -735.104% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -56.638% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -30.164% |
| Absci Corporation | 73.66 Million USD | -306.318% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -985.193% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -124.057% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -23.602% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -14.223% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -43.907% |
| Allakos Inc. | 196.05 Million USD | -52.67% |
| Imunon, Inc. | 20.31 Million USD | -1373.716% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -163.788% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 18.799% |
| BioAtla, Inc. | 129.68 Million USD | -130.8% |
| NLS Pharmaceutics AG | 11.8 Million USD | -2435.076% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -1789.276% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -252.479% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -616.792% |
| XOMA Corporation | 46.46 Million USD | -544.207% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -169.241% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -110.102% |
| aTyr Pharma, Inc. | 12.97 Million USD | -2206.172% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -188.761% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -73.146% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -17.488% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -700.144% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -3539.207% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1681.019% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -13062.795% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -4348.358% |
| UroGen Pharma Ltd. | 138.88 Million USD | -115.51% |
| Sutro Biopharma, Inc. | 243 Million USD | -23.172% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -4014.551% |
| Orgenesis Inc. | 45.75 Million USD | -554.147% |
| Entera Bio Ltd. | 8.86 Million USD | -3278.307% |
| GH Research PLC | 41.22 Million USD | -626.112% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1064.299% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -260.394% |
| Xencor, Inc. | 306.97 Million USD | 2.495% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -5966.921% |
| Replimune Group, Inc. | 234.77 Million USD | -27.493% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1360.808% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -56.061% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -4348.358% |
| Portage Biotech Inc. | 18.19 Million USD | -1544.695% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -4023.108% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -185.171% |
| OncoCyte Corporation | 25.63 Million USD | -1067.524% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -4810.389% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -2512.52% |
| Purple Biotech Ltd. | -22.46 Million USD | 1432.256% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1716.25% |
| scPharmaceuticals Inc. | 65.17 Million USD | -359.232% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -3441.078% |
| HilleVax, Inc. | 133.34 Million USD | -124.469% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2810.238% |
| Tharimmune, Inc. | 9.45 Million USD | -3065.638% |
| Genprex, Inc. | 31.06 Million USD | -863.659% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -59.614% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -853.941% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -39026.536% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -5395.18% |
| OKYO Pharma Limited | 8243.57 USD | -3630826.892% |
| Savara Inc. | 15.74 Million USD | -1801.035% |
| Curis, Inc. | 58.35 Million USD | -412.926% |
| Daré Bioscience, Inc. | 33.6 Million USD | -790.578% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -5777.638% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -3911.768% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1007.683% |
| BeiGene, Ltd. | 3.28 Billion USD | 90.893% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -1401.146% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 39.988% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -94.803% |
| Erasca, Inc. | 141.52 Million USD | -111.495% |
| bluebird bio, Inc. | 240.23 Million USD | -24.595% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -6511.878% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 82.86% |
| DBV Technologies S.A. | 92.16 Million USD | -224.781% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -6511.878% |
| Moderna, Inc. | 6.39 Billion USD | 95.319% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -602.476% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1983.517% |
| Molecular Templates, Inc. | 63.09 Million USD | -374.423% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -348.746% |
| Travere Therapeutics, Inc. | 472 Million USD | 36.585% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -108.859% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -382.133% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -589.45% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -43.813% |
| MacroGenics, Inc. | 217.21 Million USD | -37.798% |
| RenovoRx, Inc. | 11.39 Million USD | -2526.518% |
| Adicet Bio, Inc. | 152.03 Million USD | -96.871% |
| Prime Medicine, Inc. | 186.63 Million USD | -60.373% |
| Aditxt, Inc. | 25.95 Million USD | -1053.407% |
| Adagene Inc. | 41.83 Million USD | -615.535% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3994.583% |
| Quantum-Si incorporated | 111.65 Million USD | -168.064% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -74.174% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1953.25% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -735.57% |
| SciSparc Ltd. | 9.01 Million USD | -3221.696% |
| Vericel Corporation | 142.04 Million USD | -110.728% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -3357.66% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1196.389% |
| Generation Bio Co. | 144.46 Million USD | -107.188% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -260.494% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -246.192% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -1.217% |
| Invivyd, Inc. | 205.75 Million USD | -45.473% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -314.803% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -3091.532% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -297.744% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2809.672% |
| 2seventy bio, Inc. | 289.88 Million USD | -3.253% |
| ADMA Biologics, Inc. | 66.58 Million USD | -349.521% |
| Clene Inc. | 41.07 Million USD | -628.746% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -2236.982% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -446.241% |
| GeoVax Labs, Inc. | 6.02 Million USD | -4870.266% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 14.978% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -714.869% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -787.447% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -188.633% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -818.463% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -75.782% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 61.012% |
| Evaxion Biotech A/S | 22.27 Million USD | -1244.041% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -120.827% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -27.433% |
| Trevena, Inc. | 38.41 Million USD | -679.21% |
| Surrozen, Inc. | 18.55 Million USD | -1513.574% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -274.405% |
| Cingulate Inc. | 22.75 Million USD | -1215.152% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 4095.168% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -570.11% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -3535.173% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -191.852% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 60.307% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -382.195% |
| Clearmind Medicine Inc. | 8.74 Million USD | -3324.162% |
| Kronos Bio, Inc. | 128.11 Million USD | -133.627% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -256.026% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -10105.235% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -196.863% |
| Statera Biopharma, Inc. | 28.82 Million USD | -938.235% |
| ImmunityBio, Inc. | 362.87 Million USD | 17.514% |
| Korro Bio, Inc. | 84.53 Million USD | -254.08% |
| Kineta, Inc. | 21.15 Million USD | -1314.814% |
| BioVie Inc. | 31.95 Million USD | -836.826% |
| Codexis, Inc. | 66.51 Million USD | -349.98% |
| Celularity Inc. | 215.05 Million USD | -39.18% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -32.079% |
| Celcuity Inc. | 66.23 Million USD | -351.935% |
| Virax Biolabs Group Limited | 6.54 Million USD | -4471.79% |
| Cibus, Inc. | 320.3 Million USD | 6.552% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -596.088% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -784.405% |
| IN8bio, Inc. | 30.33 Million USD | -886.643% |
| Kodiak Sciences Inc. | 277.32 Million USD | -7.932% |
| Annexon, Inc. | 143.72 Million USD | -108.26% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -134.592% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1206.552% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -46668.438% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 61.606% |
| Eyenovia, Inc. | 25.4 Million USD | -1078.118% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -113.319% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -5281.481% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -278.247% |
| Arcellx, Inc. | 200.19 Million USD | -49.51% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -552.109% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -38.31% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2906.106% |
| Moolec Science SA | 52.75 Million USD | -467.421% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -389.578% |
| Geron Corporation | 70.44 Million USD | -324.92% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -543.141% |
| Royalty Pharma plc | 862.4 Million USD | 65.293% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -218.18% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -3108.858% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1222.746% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -44.033% |
| Humacyte, Inc. | 23.49 Million USD | -1173.856% |
| Structure Therapeutics Inc. | 102.77 Million USD | -191.236% |
| 89bio, Inc. | 151.2 Million USD | -97.956% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -273.531% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1958.583% |
| Genelux Corporation | 24.33 Million USD | -1129.99% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -782.345% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -73.147% |
| Notable Labs, Ltd. | 14.77 Million USD | -1926.527% |
| Liquidia Corporation | 87.98 Million USD | -240.196% |
| Mustang Bio, Inc. | 48.5 Million USD | -517.138% |
| Immunovant, Inc. | 282.7 Million USD | -5.875% |
| Quantum-Si incorporated | 111.65 Million USD | -168.064% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1227.706% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1307.429% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -193.415% |
| Acasti Pharma Inc. | 11.3 Million USD | -2548.597% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1205.862% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1773.154% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -543.114% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -26281.392% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1784.162% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -926.573% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -623.27% |
| PepGen Inc. | 84.76 Million USD | -253.111% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -910.152% |
| United Therapeutics Corporation | 885.1 Million USD | 66.183% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1207.237% |
| Solid Biosciences Inc. | 104.31 Million USD | -186.937% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -814.631% |
| Immuneering Corporation | 58.41 Million USD | -412.418% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -5780.238% |
| Silo Pharma, Inc. | 3.92 Million USD | -7532.05% |
| Belite Bio, Inc | 31.66 Million USD | -845.175% |
| XOMA Corporation | 46.46 Million USD | -544.207% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -343.106% |
| Bionomics Limited | 17.89 Billion USD | 98.327% |
| Apogee Therapeutics, Inc. | 93 Million USD | -221.837% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 938.896% |
| uniQure N.V. | 285.08 Million USD | -4.992% |
| Cassava Sciences, Inc. | 105.95 Million USD | -182.49% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3994.583% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -54.123% |
| Forte Biosciences, Inc. | 32.47 Million USD | -821.631% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -3502.441% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -918.262% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -5281.481% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -2006.39% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -3267.285% |
| Altimmune, Inc. | 30.55 Million USD | -879.572% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 30.009% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 938.896% |
| Compugen Ltd. | 43.97 Million USD | -580.717% |
| Peak Bio, Inc. | 1249.13 USD | -23962017.634% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -303.829% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1237.316% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -23.08% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -948.656% |
| Zura Bio Limited | 62.63 Million USD | -377.854% |
| PolyPid Ltd. | 21.04 Million USD | -1322.276% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1739.014% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -948.656% |
| Instil Bio, Inc. | 85.78 Million USD | -248.916% |
| argenx SE | 1.53 Billion USD | 80.482% |
| Immunome, Inc. | 122.82 Million USD | -143.705% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -517.494% |
| Verona Pharma plc | 67.15 Million USD | -345.737% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1056.338% |
| Shattuck Labs, Inc. | 93.61 Million USD | -219.736% |
| CervoMed Inc. | 14.95 Million USD | -1901.087% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -323.346% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -3403.254% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -486.898% |
| Moolec Science SA | 52.75 Million USD | -467.421% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1719.735% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -125.806% |
| AnaptysBio, Inc. | 181.56 Million USD | -64.852% |
| Design Therapeutics, Inc. | 78.19 Million USD | -282.809% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -243.882% |
| NeurAxis, Inc. | 8.82 Million USD | -3293.167% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -2278.371% |
| Lumos Pharma, Inc. | 38.66 Million USD | -674.132% |
| Achilles Therapeutics plc | 75.25 Million USD | -297.738% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1056.338% |
| 180 Life Sciences Corp. | 13.47 Million USD | -2120.872% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1029.398% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -10105.235% |
| Nutriband Inc. | 5.73 Million USD | -5120.028% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -170.191% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -437.829% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -488.294% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -352.833% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -453.032% |
| Palisade Bio, Inc. | 13.32 Million USD | -2147.132% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -559.16% |
| Beam Therapeutics Inc. | 554.19 Million USD | 45.99% |
| Neurogene Inc. | 55.58 Million USD | -438.506% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -20.455% |
| AEON Biopharma, Inc. | 48.42 Million USD | -518.055% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -209.501% |
| Sesen Bio, Inc. | 78.38 Million USD | -281.876% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -258.34% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -2278.013% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 33.631% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -240.56% |
| Athira Pharma, Inc. | 125.46 Million USD | -138.565% |
| Vaccinex, Inc. | 23.45 Million USD | -1176.137% |
| HCW Biologics Inc. | 21.02 Million USD | -1323.458% |
| XOMA Corporation | 46.46 Million USD | -544.207% |
| Nektar Therapeutics | 190.9 Million USD | -56.791% |
| Arvinas, Inc. | 480 Million USD | 37.642% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -13062.795% |
| Merus N.V. | 200.49 Million USD | -49.29% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -189.602% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -764.581% |
| Rezolute, Inc. | 70.38 Million USD | -325.246% |
| Clene Inc. | 41.07 Million USD | -628.746% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1727.508% |
| BeyondSpring Inc. | 24.86 Million USD | -1103.772% |
| Synlogic, Inc. | 58.53 Million USD | -411.375% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1572.915% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -6563.357% |
| Peak Bio, Inc. | 1249.13 USD | -23962017.634% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -395.182% |
| Krystal Biotech, Inc. | 160.42 Million USD | -86.577% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -10.6% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 13.998% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -13778.299% |
| MannKind Corporation | 125.59 Million USD | -138.316% |
| Ikena Oncology, Inc. | 84.57 Million USD | -253.9% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -3002.706% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -234.057% |
| Gossamer Bio, Inc. | 183.75 Million USD | -62.886% |
| CohBar, Inc. | 12.38 Million USD | -2316.135% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -490.091% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -985.193% |
| Legend Biotech Corporation | 583.14 Million USD | 48.672% |
| Mural Oncology plc | 192.07 Million USD | -55.837% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -345.765% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -1753.905% |
| Disc Medicine, Inc. | 91.12 Million USD | -228.47% |
| Champions Oncology, Inc. | 28.11 Million USD | -964.81% |
| REGENXBIO Inc. | 321.15 Million USD | 6.8% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -5483.006% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -436.835% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -668.257% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -161.74% |
| Vaxart, Inc. | 90.72 Million USD | -229.914% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -3413.119% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -599.438% |
| Cellectis S.A. | 97.32 Million USD | -207.561% |
| Longeveron Inc. | 21.25 Million USD | -1308.555% |
| Repare Therapeutics Inc. | 167.35 Million USD | -78.85% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 78.005% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -295.688% |
| Revolution Medicines, Inc. | 498.76 Million USD | 39.988% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -4399.669% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -580.98% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -301.284% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -329.838% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -2606.311% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 93.732% |
| Denali Therapeutics Inc. | 527.23 Million USD | 43.228% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -3357.66% |
| Veru Inc. | 101.34 Million USD | -195.336% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1178.754% |
| Cingulate Inc. | 22.75 Million USD | -1215.152% |
| Passage Bio, Inc. | 108.38 Million USD | -176.152% |
| Context Therapeutics Inc. | 25.07 Million USD | -1093.804% |
| Exicure, Inc. | 14.07 Million USD | -2026.442% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -45.255% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -591.25% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -3161.507% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -18.55% |
| Nuvalent, Inc. | 149.49 Million USD | -100.223% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -3610.445% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -188.778% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1295.487% |
| OmniAb, Inc. | 83.89 Million USD | -256.777% |
| Anew Medical, Inc. | 1.3 Million USD | -22909.576% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -813.558% |
| Lipocine Inc. | 15.08 Million USD | -1884.849% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -336.878% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -293.053% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -642.461% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -160.632% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1237.196% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 54.932% |
| Ocugen, Inc. | 71.56 Million USD | -318.235% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -218.878% |
| Q32 Bio Inc. | 92.68 Million USD | -222.959% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1313.611% |
| Alumis Inc. Common Stock | 158.17 Million USD | -89.233% |
| Equillium, Inc. | 50.6 Million USD | -491.467% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -379.63% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -2052.507% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1486.622% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -537.511% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -175.956% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -2315.271% |
| Dominari Holdings Inc. | 23.83 Million USD | -1155.792% |
| Edesa Biotech, Inc. | 9.22 Million USD | -3145.428% |
| vTv Therapeutics Inc. | 11.9 Million USD | -2413.799% |
| Bio-Techne Corporation | 563.03 Million USD | 46.839% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 26.782% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -11.372% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -126.281% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1977.011% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -82.85% |
| Nkarta, Inc. | 131.65 Million USD | -127.359% |
| BioCardia, Inc. | 12.12 Million USD | -2369.417% |
| Iterum Therapeutics plc | 47.46 Million USD | -530.568% |